---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-004937"
form_type: "8-K"
ticker: "MD"
cik: "0000893949"
company_name: "Pediatrix Medical Group, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T04:19:15.094230+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Pediatrix appoints Mark Ordan as CEO, expects 2024 adjusted EBITDA to exceed $215M guidance

## Summary
- Mark S. Ordan returns as CEO effective immediately, succeeding James D. Swift who will assist transition.
- 2024 adjusted EBITDA expected at high end of $205M-$215M range or possibly above; results due Feb 20.
- Company refocusing on hospital relationships, divesting primary/urgent care clinics, and restructuring leadership.
- Ordan led Pediatrix restructuring as CEO from 2020-2022 and has turnaround experience at Sunrise, ManorCare.
- Board cites need to accelerate strategy for shareholder value; Ordan served as Executive Chair since Oct 2024.

## SEC filing metadata
- accession: 0001193125-25-004937
- form_type: 8-K
- ticker: MD
- cik: 0000893949
- company_name: Pediatrix Medical Group, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/893949/000119312525004937/0001193125-25-004937-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/893949/000119312525004937/d843127d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-004937
- JSON: https://secwatch.observer/filing/0001193125-25-004937.json
- Plain text: https://secwatch.observer/filing/0001193125-25-004937.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.